From Medscape Diabetes & Endocrinology

Medscape Coverage from the

American Diabetes Association (ADA) 77th Scientific Sessions

June 09 - 13, 2017; San Diego, California

June 09 - 13, 2017 San Diego, California

ADA Nasal Glucagon Fixes Severe Hypoglycemia in Type 1 Diabetes Lilly plans to submit a US new drug application for the product in 2018 as a "real-world" study demonstrates efficacy.
Medscape Medical News, June 29, 2017
ADA Metformin Particularly Effective in Those With History of GDM Women who have had diabetes during pregnancy appear to profit the most from metformin treatment to reduce the risk of developing type 2 diabetes, according to the latest findings from the DPP study.
Medscape Medical News, June 29, 2017
ADA Oral Basal Insulin Shows Promise in Type 2 Diabetes A comparison with injected glargine shows no differences in glycemic control or hypoglycemia.
Medscape Medical News, June 28, 2017

Meeting Highlights At A Glance

Top News From ADA 2017: Slideshow Practice-changing results from major clinical trials in type 2 and type 1 diabetes greeted attendees here this year.

Conference News

ADA Nasal Glucagon Fixes Severe Hypoglycemia in Type 1 Diabetes
Medscape Medical News, June 29, 2017
ADA Metformin Particularly Effective in Those With History of GDM
Medscape Medical News, June 29, 2017
ADA Oral Basal Insulin Shows Promise in Type 2 Diabetes
Medscape Medical News, June 28, 2017
ADA Exercise, CBT, Diminish Diabetes-Associated Depression
Medscape Medical News, June 28, 2017
ADA 'Gamified' App Enhances Lifestyle Change in Obese Adults
Medscape Medical News, June 27, 2017
ADA Cancer Drug Imatinib May Slow New-Onset Type 1 Diabetes
Medscape Medical News, June 26, 2017
ADA Oral Insulin May Delay Type 1 Diabetes Onset in 'Responders'
Medscape Medical News, June 23, 2017
ADA SGLT1/2 Inhibitor Sotagliflozin 'Encouraging' in Type 1 Diabetes
Medscape Medical News, June 22, 2017
ADA Surgery May Help in Diabetic Neuropathy With Squeezed Leg Nerves
Medscape Medical News, June 21, 2017
ADA Occupational Therapy Helps Young Adults With Diabetes
Medscape Medical News, June 21, 2017
ADA CVD REAL: Primary Prevention for SGLT-2 Inhibitors in Diabetes?
Medscape Medical News, June 20, 2017
ADA Glucagon Receptor Antagonist Shows Early Promise in Type 1 Diabetes
Medscape Medical News, June 19, 2017
ADA CANVAS: Experts Spar on Canagliflozin Risk/Benefit in Diabetes
Medscape Medical News, June 16, 2017
ADA Single-Shot IDegLira Bests Basal-Bolus Insulin Regimen in Diabetes
Medscape Medical News, June 14, 2017

ADA No 'Vaccination' Effect Seen in Children at Risk for Diabetes
Medscape Medical News, June 14, 2017
ADA New US Healthcare Law Could Spell Disaster for Diabetes
Medscape Medical News, June 13, 2017
ADA DEVOTE: Tresiba as Safe as Glargine With Less Severe Hypoglycemia
Medscape Medical News, June 12, 2017
ADA CANVAS: Canagliflozin Reduces CV Events, but at Cost of Amputations
Medscape Medical News, June 12, 2017
ADA CV-Outcomes Trials in Diabetes Must Drive Guideline Change
Medscape Medical News, June 12, 2017
ADA REMOVAL: Mixed Data on CV Benefits of Metformin in Type 1 Diabetes
Medscape Medical News, June 12, 2017
ADA Alirocumab 'Underwhelming' in ODYSSEY Trials in Diabetes
Medscape Medical News, June 11, 2017
ADA A Perfect Twitter Storm: Why Is the ADA So Anti-Social Media?
Medscape Medical News, June 11, 2017
ADA Sexual Dysfunction in Diabetes: Underrecognized and Neglected
Medscape Medical News, June 11, 2017
ADA Boys Who Lost Weight Eliminated Risk for Diabetes as Adults
Medscape Medical News, June 11, 2017
ADA Sulfonylureas for Diabetes Still Have a Role; Cost a Big Factor
Medscape Medical News, June 10, 2017
ADA Disordered Eating Affects Swaths of Youth With Diabetes
Medscape Medical News, June 10, 2017
ADA New SUSTAIN-6 Data Could Explain Retinopathy Worsening
Medscape Medical News, June 10, 2017
ADA ADA 2017 Scientific Sessions Rich With Clinical Trials
Medscape Medical News, May 31, 2017

Popular News from ADA 2016

'New Era' of Type 2 Diabetes Treatment as LEADER Unveiled? The liraglutide trial is first to show cardiovascular benefit for a GLP-1 receptor agonist and joins EMPA-REG data in hailing a "new era" of type 2 diabetes management.
Medscape Medical News, Jun 13, 2016
Coming Soon: 'Artificial Pancreas' Options for Diabetes New data support use of a variety of partially closed-loop delivery systems using insulin and/or glucagon for treating diabetes, the so-called 'artificial' or 'bionic pancreas'.
Medscape Medical News, Jun 20, 2016
Empagliflozin Slows Progression of Renal Disease in Diabetes The long-awaited renal outcomes from the EMPA-REG trial with the SGLT-2 inhibitor for type 2 diabetes, empagliflozin indicate that the drug slows progression to kidney disease.
Medscape Medical News, Jun 14, 2016

Medscape Diabetes© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Expert Commentary

Designing the Next Generation of Diabetes Drug Trials
Lawrence A. Leiter, MD;
Mark Harmel, MPH
Type 2 Diabetes in Children Has Researchers Concerned
Dana Dabelea, MD, PhD;
Mark Harmel, MPH
Degludec Takes Insulin 'To the Next Level'
Harpreet S. Bajaj, MD, MPH
PCSK9 Therapy in Diabetes: New Context
Robert Eckel, MD
Hypoglycemia Advances: Just the 'Tip of the Iceberg'
Shivani Agarwal, MD, MPH
Confronting Insulin, Again
Christine Wiebe; Eric L. Johnson, MD
Great Minds: When Sue Met Si
Christine Wiebe, MA; Sue Carter, PhD; Seymour Reichlin, MD, PhD
New Drug Classes for Diabetes Mean New Options
Cyrus V. Desouza, MBBS
CANVAS Proves CV Safety and Metabolic Value of Canagliflozin
Clifford J. Bailey, PhD, FRCP (Edin), FRCPath; Videographer: Mark Harmel, MPH
'Eagerly Awaited' Results of CANVAS
Carol H. Wysham, MD
Poster Pearls From ADA 2017: 13 Things You'll Be Glad You Know
Laurie Scudder, DNP, NP
The Last Remnants of the Crumbling Ivory Tower: Social Media Changes Everything
John Mandrola, MD

Live Blog

News and Views from ADA 2017 Coverage of key advances and expert reactions as they happened at the meeting.

Previous Coverage